

February 20, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Update of clinical research plan of Nagoya University
(Excerpt from Japanese version)

Tokyo, February 20, 2023 – Regarding the discussion at the Certified Regenerative Medicine Committee of Nagoya University on "clinical research plan which is laid out under the initiative of Nagoya University to examine the safety and tolerability of a single administration of autologous SHED (stem cells from human exfoliated deciduous teeth) for children with cerebral palsy", the resubmitted materials were reviewed by the chairperson of the committee, and the clinical research plan was approved. Kidswell Bio Corporation will continue to collaborate with Nagoya University to initiate this clinical research.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com